As Presently, over 100 CMOs across the globe claim to have manufacturing facilities in China, offering services for pharmaceutical API, intermediates and FDF manufacturing, claims Roots Analysis

A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region.

 

• A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities.
• A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs.
• A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China.
• Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of pharmaceutical products in China. Each profile includes an overview of the company, information related to its pharmaceutical manufacturing service portfolio, details related to its manufacturing facilities, recent developments, and an informed future outlook.
• A review of the pharmaceutical manufacturing related initiatives of the top 10 big pharma players (shortlisted from the top companies of 2019 by revenues), featuring a [A] analysis by investments made, with detailed information on investments related to R&D centers and manufacturing facilities in established and emerging regions of China, [B] Harvey ball framework, presenting a summary of all initiatives
• A case study of the key recent developments (including partnerships and acquisitions) pertaining to the manufacturing of pharmaceutical drugs, during 2014-2020 (till February), based on several parameters, such as year of partnership, type of partnership and geography.

 

To order this 200+ page report, which features 85+ figures and 100+ tables, please visit  China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

 

The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:

• Key Geographical Regions
• Eastern China
• Southern China
• Northern China

 

• Type of Product
• Active Pharmaceutical Ingredients (APIs)
• Drug Products

 

• Type of Drug Product
• Solid
• Liquid / Semi-Solid
• Injectable
• Others

 

• Scale of Operation
• Clinical
• Commercial

 

• Company Size
• Small
• Mid-Sized
• Large / Very Large

 

 

The China Pharmaceutical Contract Manufacturing Services Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• 2Y-Chem
• Aurisco Pharmaceutical
• ChemPartner
• Dorrapharma
• Hubei Biocause Pharmaceutical
• Infoark
• Ningbo Menovo Pharmaceutical
• Shandong Xinhua Pharmaceutical
• Shanghai Acebright Pharmaceuticals
• STA Pharmaceutical
• Zhejiang Huahai Pharmaceutical

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Case Study: Comparison of Small Molecules and Large Molecules
 

5. Market Overview
 

6. Manufacturing Facilities of Pharmaceutical CMOs in China
 

7. Pharmaceutical Manufacturing Regulations in China
 

8. Company Profiles
 

9. Big Pharma Initiatives in China
 

10. Recent Trends
 

11. Capacity Analysis
 

12. SWOT Analysis
 

13. Market Forecast

 

14. Case Study: Impact of Coronavirus Outbreak
 

14. Conclusion

 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-pharmaceutical-contract-manufacturing/312.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]